As a Biotech company driven by in-house R&D capabilities, Hpets is committed to addressing pet medicine of unmet clinical needs in China. Launched in 2022, however, we have successfully developed a series of pet medication, including of target inflammatory, oncology, cardiovascular and other common diseases. Leveraging our advisory board’s integrated vision and industrial expertise, which of it consist of university professor, pharmaceutical R&D, professional investor and business executive etc, we are evolving to be a fully integrated biotechnology platform including preclinical evaluation, clinical trial design and execution, drug manufacturing and quality control, and commercialization. We still keep improving our specialized product pipelines around non-patent relating drugs. In the future, our discovery and development efforts are focused on from “First-Generic-Drug” to “Me-Too/Me better”, to “First-in-Class”, through diversified and multi-level cooperation models such as cooperative development, license-in, and in-depth incubation. We also vigorously explores cutting-edge technologies, such as immunotherapy to enhance our innovation capabilities. Our vision aims to become a pet medicine’s leader in China. With strong belief that precise positioning and rationally engineered, we are prepared to lead this revolution in companion animals.